esomeprazole / Generic mfg. - LARVOL DELTA

Emergency nursing care of a patient with acute appendicitis complicated by esomeprazole-induced anaphylactic shock: a case report. (PubMed, Front Surg) - "After 48 days of intensive treatment and meticulous nursing care, the patient's condition stabilized, and he was successfully discharged with good recovery at one-month follow-up. Rapid recognition of drug allergy, efficient multidisciplinary collaboration, precise VA-ECMO circuit management, systematic temperature control, and comprehensive psychological support are critical to improving survival and neurological outcomes in patients with esomeprazole-induced anaphylactic shock complicated by cardiac arrest."

Journal • Allergy • Cardiovascular • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Urticaria

Bacillus Probiotics With Bismuth Quadruple Therapy for Helicobacter Pylori Infection (clinicaltrials.gov) - P=N/A | N=336 | Not yet recruiting | Sponsor: Anabio R&D

New trial • Infectious Disease

Esomeprazole inhibits EGF-induced invasion and migration of gastric cancer cells. (PubMed, PeerJ) - "This study aims to investigate the inhibitory effect of ESO on EGF-induced invasion and migration of gastric cancer cells, and its relationship with the EGFR/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway. The combination of ESO and afatinib (an irreversible EGFR inhibitor) led to a more pronounced reduction in cell viability, invasion, migration, and protein expression compared to either treatment alone. ESO inhibits EGF-induced invasion and migration in GC cells potentially via the EGFR/AKT/mTOR pathway, offering a potential new strategy for GC treatment."

Journal • Gastric Cancer • Oncology • Solid Tumor • CDH2 • MMP2 • MMP9 • VIM

Potential Drug-Drug Interactions in Patients Undergoing Hemodialysis: A Retrospective Observational Study. (PubMed, Saudi Med J) - "In total, 4,157 pDDIs were identified, most of which were Category C (75.4%), followed by Categories B and D. Category X interactions were uncommon (n = 78), with clopidogrel-omeprazole and clopidogrel-esomeprazole being the most frequent. The pDDIs are highly prevalent among patients with ESRD undergoing HD, with polypharmacy identified as the main determinant. These findings highlight the importance of structured medication review, multidisciplinary collaboration, and clinical pharmacist involvement to reduce medication-related risks and optimize patient outcomes."

Journal • Observational data • Retrospective data • Chronic Kidney Disease • Nephrology • Renal Disease

Comparative effectiveness of genotype-guided and empirical bismuth-containing quadruple therapy for Helicobacter pylori eradication: a retrospective study. (PubMed, Front Pharmacol) - "All regimens comprised bismuth potassium citrate 2.6 g, a proton pump inhibitor (PPI, esomeprazole 20 mg or ilaprazole 5 mg) or a potassium-competitive acid blocker (P-CAB, keverprazan 20 mg or tegoprazan 50 mg), and antibiotics selected from amoxicillin, clarithromycin, levofloxacin, furazolidone, tetracycline, metronidazole, or doxycycline. Dual clarithromycin and levofloxacin resistance and alcohol consumption remained key determinants of treatment failure even with genotype-guided therapy. However, the precision of estimates for single-drug resistance subgroups was limited by small sample sizes and should be interpreted cautiously."

HEOR • Journal • Retrospective data • Addiction (Opioid and Alcohol) • Infectious Disease

Short-Term Efficacy of Tegoprazan Compared With Esomeprazole in Patients With Non-Erosive Reflux Disease and Nocturnal Heartburn Symptoms: A Double-Blind, Randomized Controlled Trial. (PubMed, Korean J Helicobacter Up Gastrointest Res) - "The time to the first nocturnal heartburn-free interval was shorter with tegoprazan than with esomeprazole (2.0 days vs. 2.5 days, p=0.529); however, the difference was not significant. Tegoprazan demonstrated non-inferiority to esomeprazole with respect to nocturnal heartburn-free days and may provide more rapid relief from nocturnal heartburn symptoms."

Journal • Gastroenterology • Gastroesophageal Reflux Disease

A multicenter, randomized, double-blind, double-dummy phase II clinical trial to evaluate the efficacy and safety of injectable LX22001 versus esoprazole sodium for injection in reducing the risk of rebleeding after endoscopic treatment for peptic ulcer bleeding (ChiCTR) - P2 | N=195 | Completed | Sponsor: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting ➔ Completed

Trial completion • Gastroenterology • Peptic Ulcer • GAST

Posterior Reversible Encephalopathy Syndrome Associated With Severe Proton Pump Inhibitor-Induced Hypomagnesemia: A Rare Case. (PubMed, Cureus) - "The patient showed severe hypomagnesemia after prolonged proton pump inhibitor (PPI) use, where the onset of neurological symptoms occurred after the increase of esomeprazole (40 mg/day)...In patients with PRES and no clear trigger, serum magnesium should be monitored, especially in long-term PPI users. This case highlights a reversible and preventable cause of PRES, supporting the need to monitor serum magnesium and prescribe PPIs with caution in clinical practice."

Journal • Cardiovascular • CNS Disorders • Hypertension

Bismuth Quadruple Therapy Versus Modified Bismuth Therapy for Helicobacter Pylori (clinicaltrials.gov) - P3 | N=200 | Completed | Sponsor: Reham Abdelkader Elkhouly

New P3 trial • Infectious Disease

Beyond acid suppression: the multifaceted role of proton pump inhibitors in Helicobacter pylori eradication. (PubMed, Front Microbiol) - "This review provides a comprehensive overview of the pharmacological properties, clinical applications, and current limitations of the most widely used PPIs, including omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and rabeprazole. The review also discusses emerging evidence for interindividual variability in PPI metabolism, drug-drug interactions, and concerns regarding long-term adverse effects of the current treatments. Finally, it highlights potassium-competitive acid blockers (P-CABs), a newer class of acid-suppressive agents that provide sustained acid inhibition and represent a promising alternative to PPI-based regimens for H. pylori eradication."

Journal • Review • Infectious Disease

Differential fracture risk among proton pump inhibitors in older adults: evidence network and pharmacovigilance validation. (PubMed, Front Pharmacol) - "Compared with non-PPI users, omeprazole (OR 1.51, 95%CI 1.36-1.67), rabeprazole (OR 1.47, 95%CI 1.22-1.78), pantoprazole (OR 1.44, 95%CI 1.28-1.62), and lansoprazole (OR 1.32, 95%CI 1.14-1.53) were associated with a significantly increased risk of any-site fracture...Consistent with NMA findings, omeprazole exhibited a significant fracture risk signal (ROR 1.25, 95%CI 1.03-1.51), while esomeprazole showed no significant signal for overall fracture (ROR 0.89, 95%CI 0.66-1.20)...This discordance indicates that absence of a fracture signal should not imply skeletal safety. These findings provide evidence-based guidance for individualized PPI prescribing in elderly patients, with careful benefit-risk assessment for those requiring extended-duration PPI regimens."

Adverse events • Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • ROR1

AWaRe-aligned doxycycline-based bismuth quadruple therapy achieves high Helicobacter pylori eradication rates and supports antimicrobial stewardship. (PubMed, Gastroenterol Hepatol) - "This AWaRe-aligned doxycycline-based quadruple therapy achieved an acceptable eradication rate in the PP/mITT populations, with good tolerability. However, the lower ITT eradication rate warrants cautious interpretation of its overall effectiveness."

Journal • Infectious Disease

COMPARISON OF KEVERPRAZAN-BASED VERSUS ESOMEPRAZOLE-BASED DUAL THERAPY FOR INITIAL TREATMENT OF HELICOBACTER PYLORI INFECTION: A PROSPECTIVE, MULTICENTER, RANDOMIZED CONTROLLED TRIAL (UEGW 2026) - No abstract available

Clinical • Infectious Disease

When Acid Suppression Fails: Isolated Hepatic Artery Vasculitis Masquerading as Refractory GERD (ACG 2026) - "Case Description/ A 54-year-old male with refractory GERD on esomeprazole and famotidine, Schatzki ring, obesity, and MASLD presented with chest pain radiating to the back and epigastric pain radiating to the right and left upper quadrants...The patient was treated with high-dose prednisone on a 12-week taper...No aortic or aortic branch involvement was identified. Figure: CT abdomen with contrast (coronal view) obtained 3 years prior to diagnosis showing normal caliber and wall thickness of the common hepatic artery (red arrow) without evidence of perivascular inflammation, serving as a baseline comparison and confirming the de novo development of vasculitis identified on subsequent imaging."

Cardiovascular • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Inflammation • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Vasculitis

Sporadic Fundic Gland Polyps With Low-Grade Dysplasia in Chronic Proton Pump Inhibitor Users: A Two Patient Case Series (ACG 2026) - "Case Description/ Patient 1 was a 62-year-old female with non-dysplastic short-segment Barrett's esophagus on esomeprazole 40 mg twice daily for 14 years...Patient 2 was a 68-year-old male with chronic GERD on omeprazole 20 mg daily for at least 10 years...(B) Higher-power view showing epithelial cytologic atypia consistent with low-grade dysplasia. (C) Additional low-power section highlighting glandular architecture and cystic dilatation within the lesion."

Clinical • Barrett Esophagus • Colorectal Cancer • Gastric Cancer • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Solid Tumor

Longitudinal Gut Resistome Remodeling and Phenotype-Specific Refractory GERD Outcomes During P-CAB Versus PPI Therapy: Prospective Multicenter Data from India (ACG 2026) - "A total of 1,300 patients were enrolled, including 783 males (60.2%) and 517 females (39.8%). Patients received either vonoprazan-based P-CAB therapy (20 mg daily; n=650) or esomeprazole/rabeprazole-based PPI therapy (40 mg daily; n=650). Mean age was 44.6±11.8 years (95% CI 43.9â45.2)."

Clinical • Gastroenterology • Gastroesophageal Reflux Disease • Immunology

Proton Pump Inhibitor-Associated Rhabdomyolysis: A Systematic Review of Pharmacovigilance Disproportionality Studies (ACG 2026) - "Pantoprazole was the weakest and nonsignificant in the Italian data (ROR 1.15; 95% CI 0.90-1.49). From 251 records, 196 were screened after duplicate removal. A disproportionate signal linking PPIs to rhabdomyolysis was identified across all three databases, with the magnitude varying by agent. In FAERS, all five PPIs showed significant RORs, with lansoprazole the strongest (ROR 12.67; 95% CI 11.66-13.77); esomeprazole, omeprazole, and rabeprazole were consistently significant across FAERS and JADER."

Adverse events • Review • Musculoskeletal Pain • ROR1

Concomitant Proton Pump Inhibitor Use and IBD-Related Outcomes After GLP-1 Receptor Agonist Initiation (ACG 2026) - "Adults with Crohnâs disease or ulcerative colitis initiating GLP-1 therapy were stratified by PPI exposure, defined by omeprazole, pantoprazole, lansoprazole, esomeprazole, rabeprazole, or dexlansoprazole use. Before propensity score matching, 8,329 patients were identified in the PPI-exposed cohort and 4,504 in the non-PPI-exposed cohort. After matching, 2,943 patients remained in each cohort. Among patients eligible for incident outcome analysis after excluding those with the composite outcome before initiating GLP-1 therapy, the primary outcome occurred in 210/648 patients (32.4%) with PPI exposure and 140/710 patients (19.7%) without PPI exposure."

Crohn's disease • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammatory Bowel Disease • Obesity • Ulcerative Colitis

Efficacy and Safety of Zastaprazan, a Novel Potassium-Competitive Acid Blocker in Indian Patients With Erosive Esophagitis: A Phase 3, Multicenter, Randomized, Active-Controlled Study (ACG 2026) - "The cumulative rate of healing at week 8, was 99.06%(105/106) in test arm and 98.13%(105/107) in reference arm with a difference of 0.93 (95% confidence interval â2.23; 4.08, P= 0.5929) demonstrating non-inferiority of Zastaprazan to Esomeprazole. The healing rate at week 4 was 70.75%(75/106) in test arm and 66.36%(71/107) in reference arm. The reduction in FSSG and GERD-HRQL scores from baseline was statistically significant in both the groups (p< 0.0001)."

Clinical • P3 data • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

Not All Proton Pump Inhibitors Are Equal: A Head-to-Head Safety Comparison of All Six Oral Agents in 954,252 Propensity-Matched Adults (ACG 2026) - "Six mutually exclusive cohorts excluded other study PPIs, H2-receptor antagonists, or vonoprazan within 1 year before or any time after index. 954,252 patients met criteria (pantoprazole 247,382; omeprazole 562,141; esomeprazole 87,754; lansoprazole 35,077; dexlansoprazole 13,297; rabeprazole 8,601). All post-match standardized mean differences were < 0.10. Dexlansoprazole and rabeprazole showed the lowest adverse-event burden â each significantly more favorable than the other four, with no significant difference between them (RR 1.008, 95% CI 0.927â1.095)."

Clinical • Head-to-Head • Acute Kidney Injury • Alzheimer's Disease • Chronic Kidney Disease • CNS Disorders • Dementia • Hematological Disorders • Infectious Disease • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Pneumonia • Renal Disease • Respiratory Diseases

Beyond Acid Suppression: Real-World Enteric Infection and All-Cause Mortality Outcomes With Vonoprazan Versus Proton Pump Inhibitor in Gastroesophageal Reflux Disease (ACG 2026) - "The exposure group included vonoprazan monotherapy, and the comparator group included pooled PPI monotherapy (dexlansoprazole, esomeprazole, rabeprazole, lansoprazole, omeprazole, and pantoprazole). After PSM, 6,721 patients were included in each cohort. Vonoprazan was associated with a higher risk of non-CDI enteric infection compared with pooled PPIs (5.6% vs 2.5%; RR 2.23; OR 2.30; HR 2.69, 95% CI 2.21â3.27). This association remained consistent across all individual PPI subgroup analyses."

Clinical • Real-world • Real-world evidence • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Infectious Disease

Insurance Coverage and Patient Out-of-Pocket Costs Influence Physicians in Choosing Off-Label Over FDA-Approved Treatments for Patients With Eosinophilic Esophagitis: Results From a U.S. Physician Survey (ACG 2026) - "PPIs were dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole and vonoprazan (although vonoprazan is not a PPI, it is a potassium-competitive acid blocker and is included as part of this group for the purposes of this survey); â For example, elemental diet, 6-/4-/2-food elimination diet; â¡Off-label swallowed topical corticosteroids were inhaled budesonide and fluticasone propionate formulations that are swallowed, rather than inhaled (off-label use); §Systemic corticosteroids were betamethasone, hydrocortisone and prednisone. In total, 100 physicians completed the survey (gastroenterologists, 36%; allergists/immunologists, 35%; primary care providers, 29%); the majority had been practicing for >15 years. Proton-pump inhibitors (PPIs), dietary intervention and off-label swallowed topical corticosteroids were the most common first-line treatments for adults with EoE. FDA-approved treatments, BOS and dupilumab, were..."

Clinical • Reimbursement • US reimbursement • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology

Vonoprazan Versus Esomeprazole for H. pylori Eradication in Treatment Naïve Patients: A Regimen-Stratified Meta-Analysis of Randomized Controlled Trials (ACG 2026) - "Ten RCTs (n=3,045) were included. VPZ-based regimens achieved eradication rates equivalent to ESO-based regimens overall (RR=1.02, 95% CI: 0.93-1.12; I²=77.3%), with consistent findings across all four regimen-specific subgroups: VPZ dual vs. ESO quadruple (RR=1.00), VPZ triple vs."

Retrospective data • Constipation • Gastroenterology • Gastrointestinal Disorder

GMPA Versus PPI for Gastric Protection and aGVHD Risk (clinicaltrials.gov) - P=N/A | N=198 | Recruiting | Sponsor: First Affiliated Hospital of Zhejiang University

New trial • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Neutropenia • Transplantation

TEGOPRAZAN-AMOXICILLIN DUAL THERAPY VERSUS ESOMEPRAZOLE-BASED BISMUTH QUADRUPLE THERAPY FOR FIRST-LINE HELICOBACTER PYLORI ERADICATION: A PROSPECTIVE, RANDOMIZED, MULTICENTER, SUPERIORITY TRIAL (UEGW 2026) - No abstract available

Clinical • Head-to-Head • Infectious Disease